参考文献

[1]Bonow RO,Carabello BA,Chatterjee K,et al.ACC/AHA 2006 guidelines for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease).J Am Coll Cardiol,2006,48:e1-e148.

[2]Bonow RO,Carabell B,Chatterjee K,et al.2008 Focused update incorporrated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(writing committee to revise the 2006 guidelines for the management of patients with valvular heart disease).Circulation,2008,118:e523-e661.

[3]Wilson W,Taubert KA,Gewitz M,et al.Prevention of infective endocarditis:guidelines from the American Heart Association:a guidelines from the American Heart Association Rheumatic Fever,Endocarditis,and Kawasaki Disease Committee,Council on Cardiovascular Disease in the Young,and the Council on Clinical Cardiology,Council on Cardiovascular Surgery and Anesthesia,and the Quality of Care and Outcomes Research Interdisciplinary Working Group.Circulation,2007,116:1736-1754.

[4]Vahainan A,Baumgartner H,Bax J,et al.Guidelines on the management of valvular heart disease:the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology.Eur Heart J,2007,28:230-268.

[5]Rossi A,Dini FL,Faggiano P,et al.Independent prognostic value of functional mitral regurgitation in patients with heart failure.A quantitative analysis of 1256 patients with ischaemic and nonischaemic dilated cardiomyopathy.Heart,2011,97:1675-1680.

[6]Seiffert M,Conradi L,Baldus S,et al.Transcatheter mitral valve-in-valve implantation in patients with degenerated bioprostheses.JACC Cardiovasc Interv,2012,5:341-349.(https://www.daowen.com)

[7]Schofer J,Siminiak,T,Haude M,et al.Percutaneous mitral annuloplasty for functional mitral regurgitation:results of the CARILLON Mitral Annuloplasty Device European Union Study.Circulation,2009,120:326-333.

[8]Harnek J,Webb JG,Kuck KH,et al.Transcatheter implantation of the MONARC coronary sinus device for mitral regurgitation:1-year results from the EVOLUTION phase Istudy(clinical evaluation of the edwards lifesciences percutanrous mitral annuloplasty system for the treatment of mitral regurgitation).JACC Cardiovasc Interv,2011,4:115-122.

[9]Silvestry FE,Rodriguez LL,Herrmann HC,et al.Echocardiographic guidance and assessment of percutanrous repair for mitral regurgitation with the Evalve MitraClip:lessons learned from EVEREST I.J Am Soc Echocardiogr,2007,20:1131-1140.

[10]Whitlow PL,Feldman T,Pedersen WR,et al.EVERESTⅡInvestigators.Acute and 12-month results with catheter-based mitral valve leaflet repair:the EVERESTⅡ(endovascular valve Edge-to-Edge repair)high risk study.J Am Coll Cardiol,2012,59:130-139.

[11]Jilaihawi H,Hussaini A,Kar S.MitraClip:a novel percutaneous approach to mitral valve repair.J Zhejiang Univ Sci B,2011,12:633-637.

[12]Holmes DR,Jr,Mack MJ,Kaul S,et al.2012 ACCF/AATS/SCAI/STSexpert consensus document on transcatheter aortic valve replacement.J Am Coll Cardiol,2012,59:1200-1254.